{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:31:27Z","timestamp":1793413887157,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10067-024-06940-5","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:02:26Z","timestamp":1711105346000},"page":"1605-1613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"43","author":[{"given":"Qianqian","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6839-9539","authenticated-orcid":false,"given":"Chijin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"6940_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945","journal-title":"JAMA"},{"key":"6940_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","volume":"157","author":"P Gisondi","year":"2007","unstructured":"Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case\u2013control study. Br J Dermatol 157:68\u201373","journal-title":"Br J Dermatol"},{"key":"6940_CR3","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735\u20131741","journal-title":"JAMA"},{"key":"6940_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.mcna.2009.08.003","volume":"93","author":"D Levine","year":"2009","unstructured":"Levine D, Gottlieb A (2009) Evaluation and management of psoriasis: an internist\u2019s guide. Med Clin North Am 93:1291\u20131303","journal-title":"Med Clin North Am"},{"issue":"1","key":"6940_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","volume":"52","author":"P Mease","year":"2005","unstructured":"Mease P, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52(1):1\u201319","journal-title":"J Am Acad Dermatol"},{"key":"6940_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1468-3083.2011.03985.x","volume":"25","author":"Q Yang","year":"2011","unstructured":"Yang Q, Qu L, Tian H et al (2011) Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol 25:1409\u20131414","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"45","key":"6940_CR7","first-page":"385","volume":"2018","author":"JC-C Wei","year":"2000","unstructured":"Wei JC-C, Shi L-H, Huang J-Y et al (2000) Epidemiology and medication pattern change of psoriatic diseases in Taiwan from 2000 to 2013: a nationwide, population-based cohort study. J Rheumatol 2018(45):385\u2013392","journal-title":"J Rheumatol"},{"key":"6940_CR8","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1756-185X.14185","volume":"24","author":"A Chopra","year":"2021","unstructured":"Chopra A, Lin H-Y, Navarra SV et al (2021) Rheumatoid arthritis management in the APLAR region: perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases. Int J Rheum Dis 24:1106\u20131111","journal-title":"Int J Rheum Dis"},{"key":"6940_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/1756-185X.13091","volume":"20","author":"M Lahiri","year":"2017","unstructured":"Lahiri M, Santosa A, Teoh LK et al (2017) Use of complementary and alternative medicines is associated with delay to initiation of disease-modifying anti-rheumatic drug therapy in early inflammatory arthritis. Int J Rheum Dis 20:567\u2013575","journal-title":"Int J Rheum Dis"},{"key":"6940_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","volume":"336","author":"RS Stern","year":"1997","unstructured":"Stern RS, Nichols KT, Vakeva LH (1997) Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA) The PUVA Follow-Up Study. N Engl J Med 336:1041\u201345","journal-title":"N Engl J Med"},{"key":"6940_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/0190-9622(93)70283-Y","volume":"29","author":"HM Studniberg","year":"1993","unstructured":"Studniberg HM, Weller P (1993) PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 29:1013\u20131022","journal-title":"J Am Acad Dermatol"},{"key":"6940_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","volume":"148","author":"S Hsu","year":"2012","unstructured":"Hsu S, Papp KA, Lebwohl MG et al (2012) Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 148:95\u2013102","journal-title":"Arch Dermatol"},{"key":"6940_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1476-5381.2010.00702.x","volume":"160","author":"W Weger","year":"2010","unstructured":"Weger W (2010) Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 160:810\u2013820","journal-title":"Br J Pharmacol"},{"issue":"suppl 2","key":"6940_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","volume":"23","author":"D Pathirana","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P et al (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(suppl 2):1\u201370","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"6940_CR15","volume":"2013","author":"DS Dubois","year":"2013","unstructured":"Dubois DS, Pouliot R (2013) Promising new treatments for psoriasis. Sci World J 2013:980419","journal-title":"Sci World J"},{"key":"6940_CR16","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665\u20131674","journal-title":"Lancet"},{"key":"6940_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J et al (2014) Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70:871\u2013881","journal-title":"J Am Acad Dermatol"},{"key":"6940_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaad.2012.06.035","volume":"68","author":"H Yeung","year":"2013","unstructured":"Yeung H, Wan J, Van Voorhees AS et al (2013) Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 68:64\u201372","journal-title":"J Am Acad Dermatol"},{"key":"6940_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2133.2005.06563.x","volume":"152","author":"L Naldi","year":"2005","unstructured":"Naldi L, Griffiths CE (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152:597\u2013615","journal-title":"Br J Dermatol"},{"key":"6940_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","volume":"164","author":"R Gniadecki","year":"2011","unstructured":"Gniadecki R, Kragballe K, Dam TN, Skov L (2011) Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 164:1091\u20131096","journal-title":"Br J Dermatol"},{"key":"6940_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273\u2013287","journal-title":"Immunol Rev"},{"key":"6940_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K de Vlam","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ (2014) Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol 94:627\u2013634","journal-title":"Acta Derm Venereol"},{"key":"6940_CR23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537\u20131550","journal-title":"N Engl J Med"},{"key":"6940_CR24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525\u20131536","journal-title":"N Engl J Med"},{"key":"6940_CR25","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Coates LC, Fleishaker D et al (2021) Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol 3:e270\u2013e283","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"6940_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","volume":"6","author":"S Sarabia","year":"2022","unstructured":"Sarabia S, Ranjith B, Koppikar S, Wijeratne DT (2022) Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol 6(1):71. https:\/\/doi.org\/10.1186\/s41927-022-00287-7","journal-title":"BMC Rheumatol"},{"issue":"1","key":"6940_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/1756-185X.14447","volume":"26","author":"P Harkins","year":"2023","unstructured":"Harkins P, Burke E, Swales C, Silman A, Conway R (2023) Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. Int J Rheum Dis 26(1):31\u201342. https:\/\/doi.org\/10.1111\/1756-185X.14447. (Epub 2022 Oct 2)","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"6940_CR28","first-page":"412","volume":"151","author":"YC Tsai","year":"2016","unstructured":"Tsai YC, Tsai TF (2016) A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol 151(4):412\u2013431 (Epub 2016 Feb 18)","journal-title":"G Ital Dermatol Venereol"},{"key":"6940_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002559","volume":"9","author":"X Leng","year":"2023","unstructured":"Leng X et al (2023) Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open 9:e002559","journal-title":"RMD Open"},{"key":"6940_CR30","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71.\u00a0https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"6940_CR31","doi-asserted-by":"publisher","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898.\u00a0https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"issue":"11","key":"6940_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"7109","key":"6940_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Res ed) 315(7109):629\u2013634","journal-title":"BMJ (Clinical Res ed)"},{"key":"6940_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H et al (2015) Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386:552\u2013561","journal-title":"Lancet"},{"key":"6940_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA et al (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 74:841\u2013850","journal-title":"J Am Acad Dermatol"},{"key":"6940_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","volume":"88","author":"J Zhang","year":"2017","unstructured":"Zhang J et al (2017) The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 88:36\u201345","journal-title":"J Dermatol Sci"},{"issue":"5","key":"6940_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/intimm\/dxt062","volume":"26","author":"M Ishizaki","year":"2014","unstructured":"Ishizaki M, Muromoto R, Akimoto T et al (2014) Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 26(5):257\u2013267","journal-title":"Int Immunol"},{"issue":"5","key":"6940_CR38","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD (2023) Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci 24(5):4901","journal-title":"Int J Mol Sci"},{"issue":"5","key":"6940_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1615\/CritRevImmunol.2020033243","volume":"39","author":"F Caso","year":"2019","unstructured":"Caso F, Costa L, Chimenti MS, Navarini L, Punzi L (2019) Pathogenesis of psoriatic arthritis. Crit Rev Immunol 39(5):361\u2013377","journal-title":"Crit Rev Immunol"},{"key":"6940_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109853","volume":"143","author":"C Marasca","year":"2020","unstructured":"Marasca C, Ruggiero A, Napolitano M et al (2020) May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses 143:109853","journal-title":"Med Hypotheses"},{"issue":"5","key":"6940_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","volume":"32","author":"F Caso","year":"2023","unstructured":"Caso F, Costa L, Triggianese P et al (2023) Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opin Investig Drugs 32(5):361\u2013371","journal-title":"Expert Opin Investig Drugs"},{"key":"6940_CR42","doi-asserted-by":"crossref","unstructured":"Tomura M, Honda T, Tanizaki H, Otsuka A, Egawa G, Tokura Y, Waldmann H, Hori S, Cyster JG, Watanabe T, Miyachi Y, Kanagawa O, Kabashima K (2010) Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 120(3):883\u2013893","DOI":"10.1172\/JCI40926"},{"key":"6940_CR43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.2585","volume":"14","author":"EE Gray","year":"2013","unstructured":"Gray EE, Ram\u00edrez-Valle F, Xu Y, Wu S, Wu Z, Karjalainen KE, Cyster JG (2013) Deficiency in IL-17-committed V\u03b34(+) \u03b3\u03b4 T cells in a spontaneous Sox13-mutant CD45.1(+) congenic mouse substrain provides protection from dermatitis. Nat Immunol 14:584\u2013592","journal-title":"Nat Immunol"},{"issue":"8","key":"6940_CR44","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.3390\/ijms23084457","volume":"23","author":"T Tashiro","year":"2022","unstructured":"Tashiro T, Sawada Y (2022) Psoriasis and systemic inflammatory disorders. Int J Mol Sci 23(8):4457","journal-title":"Int J Mol Sci"},{"key":"6940_CR45","doi-asserted-by":"publisher","unstructured":"Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D (2024) Tofacitinib efficacy in patients with rheumatoid arthritis and probable depression\/anxiety: post hoc analysis of phase 3 and 3b\/4 randomized controlled trials. Rheumatol Ther 11(1):35\u201350.\u00a0https:\/\/doi.org\/10.1007\/s40744-023-00612-7","DOI":"10.1007\/s40744-023-00612-7"},{"key":"6940_CR46","doi-asserted-by":"publisher","unstructured":"Sui S, Lv H (2022) Cognitive improving actions of tofacitinib in a mouse model of Alzheimer disease involving TNF-\u03b1, IL-6, PI3K-Akt and GSK-3\u03b2 signalling pathway. Int J Neurosci. https:\/\/doi.org\/10.1080\/00207454.2022.2151712","DOI":"10.1080\/00207454.2022.2151712"},{"key":"6940_CR47","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616\u2013624","journal-title":"N Engl J Med"},{"key":"6940_CR48","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Eng J Med 376:1723\u20131736","journal-title":"N Eng J Med"},{"issue":"4","key":"6940_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.rdc.2018.06.008","volume":"44","author":"T Kapoor","year":"2018","unstructured":"Kapoor T, Bathon J (2018) Renal manifestations of rheumatoid arthritis. Rheum Dis Clin North Am 44(4):571\u2013584","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"6940_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13256-023-03821-4","volume":"17","author":"M Mardani","year":"2023","unstructured":"Mardani M, Mohammadshahi J, Abolghasemi S, Teimourpour R (2023) Drug-induced liver injury due to tofacitinib: a case report. J Med Case Rep 17(1):97","journal-title":"J Med Case Rep"},{"key":"6940_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116137","volume":"153","author":"B Batteux","year":"2021","unstructured":"Batteux B, Bennis Y, Bodeau S, Masmoudi K, Hurtel-Lemaire AS, Kamel S, Gras-Champel V, Liabeuf S (2021) Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase\u00ae). Bone 153:116137","journal-title":"Bone"},{"issue":"6","key":"6940_CR52","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81(6):798\u2013804. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915. (Epub 2022 Jan 13)","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6940_CR53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jiac.2017.03.002","volume":"23","author":"K Yanagisawa","year":"2017","unstructured":"Yanagisawa K, Ogawa Y, Hosogai M, Todokoro D, Mitsui T, Yokohama A, Kishi S, Handa H (2017) Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy. J Infect Chemother 23(8):572\u2013575","journal-title":"J Infect Chemother"},{"issue":"5","key":"6940_CR54","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/09273948.2022.2069128","volume":"31","author":"K Baquet-Walscheid","year":"2023","unstructured":"Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A (2023) Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report. Ocul Immunol Inflamm 31(5):1079\u20131080","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"6940_CR55","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B (2023) Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis 82(7):901\u2013910. https:\/\/doi.org\/10.1136\/ard-2022-223715. (Epub 2023 Mar 17)","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06940-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T02:03:44Z","timestamp":1713146624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06940-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6940"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06940-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"assertion":[{"value":"3 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}